The Treatment of High-Risk Smoldering Myeloma
Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the standard of care for patients with high-risk smoldering myeloma.
Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the standard of care for patients with high-risk smoldering myeloma.
The current standard of care for these patients is to follow and check blood test, though there is no evidence to suggest this is the best practice, Landgren says.
In his presentation at the 17th International Congress on Hematologic Malignancies, Landgren gave an overview of the landscape regard other options in this disease type: ongoing studies, imaging, and molecular profiling studies.
Clinical Pearls
Landgren believes that there will soon be a change in the standard of care, though it is not time to start treating patients outside of clinical trials.
- The current standard of care for patients with high-risk smoldering myeloma is to follow and check blood tests
- Landgren predicts a change in the standard of care in the near future
Fellow's Perspective: Impact of Quadruplet and MRD in Newly Diagnosed Multiple Myeloma
December 17th 2024In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about how recent trials shape their approach for a patient with transplant-eligible multiple myeloma.
Read More
